Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Morphothiadine Mesilate/Ritonavir with Entecavir or Tenofovir in Healthy Subjects
NCT03662568Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mofesertib in Chronic Hepatitis B (CHB) (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 3 more. Started Jun 2018; status: completed.
02
Drugs
mofesertib
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03662568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662568.